Entegrion, Inc.   Report issue

For profit Phase 2
Founded: Raleigh NC United States (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2013
NCT01589666
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Entegrion, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

blood plasma (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blood Coagulation Disorders (Phase 2)

Hemostatic Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1